FDA aims to publish Essure safety review in February

This product image provided by Bayer Healthcare Pharmaceuticals, Inc. shows the birth control implant called Essure. Federal medical experts on Monday, Sept. 21, 2015 said it will take a closer look at a host of problems reported with Essure, including chronic pain, bleeding, headaches and allergic reactions. (Bayer Healthcare Pharmaceuticals, Inc. via AP)

WASHINGTON (AP) – Federal health officials aim to complete their review of a much-debated contraceptive implant by the end of February.

The Food and Drug Administration posted a brief statement online about the metallic device, Essure, which has been subject to thousands of complaints by women reporting chronic pain, bleeding and headaches.

The implant has been sold for more than a decade and is frequently pitched to women as the only non-surgical option for permanent birth control. While Essure’s label warns of pain and bleeding after implantation, some women say these problems persist and can be so severe they require surgery to remove the device.

In September, the FDA convened a public meeting on the issue where dozens of women urged the agency to recall the device.

(Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s